Development of SARS-CoV-2 Vaccine: Challenges and Prospects
The WHO declared coronavirus disease 2019 (COVID-19) a pandemic in March 2020, which was caused by novel coronavirus severe acute respiratory coronavirus 2 (SARS-CoV-2). SARS-CoV-2 made its first entry into the world in November 2019, and the first case was detected in Wuhan, China. Mutations in the...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | en en |
| Published: |
MDPI
2023
|
| Subjects: | |
| Online Access: | https://eprints.ums.edu.my/id/eprint/36746/1/ABSTRACT.pdf https://eprints.ums.edu.my/id/eprint/36746/2/FULL%20TEXT.pdf https://eprints.ums.edu.my/id/eprint/36746/ https://doi.org/10.3390/diseases11020064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1831795737059393536 |
|---|---|
| author | Tooba Mahboob Amni Adilah Ismail Muhammad Raza Shah Mohammed Rahmatullah Alok K. Paul Maria de Lourdes Pereira Christophe Patrice Andie Wiart Polrat Wilairatana Mogana Rajagopal Karma G. Dolma Veeranoot Nissapatorn |
| author_facet | Tooba Mahboob Amni Adilah Ismail Muhammad Raza Shah Mohammed Rahmatullah Alok K. Paul Maria de Lourdes Pereira Christophe Patrice Andie Wiart Polrat Wilairatana Mogana Rajagopal Karma G. Dolma Veeranoot Nissapatorn |
| author_sort | Tooba Mahboob |
| building | UMS Library |
| collection | Institutional Repository |
| content_provider | Universiti Malaysia Sabah |
| content_source | UMS Institutional Repository |
| continent | Asia |
| country | Malaysia |
| description | The WHO declared coronavirus disease 2019 (COVID-19) a pandemic in March 2020, which was caused by novel coronavirus severe acute respiratory coronavirus 2 (SARS-CoV-2). SARS-CoV-2 made its first entry into the world in November 2019, and the first case was detected in Wuhan, China. Mutations in the SARS-CoV-2 genome distressed life in almost every discipline by the extended production of novel viral variants. In this article, authorized SARS-CoV-2 vaccines including mRNA vaccines, DNA vaccines, subunit vaccines, inactivated virus vaccines, viral vector vaccine, live attenuated virus vaccines and mix and match vaccines will be discussed based on their mechanism, administration, storage, stability, safety and efficacy. The information was collected from various journals via electronic searches including PubMed, Science Direct, Google Scholar and the WHO platform. This review article includes a brief summary on the pathophysiology, epidemiology, mutant variants and management strategies related to COVID-19. Due to the continuous production and unsatisfactory understanding of novel variants of SARS-CoV-2, it is important to design an effective vaccine along with long-lasting protection against variant strains by eliminating the gaps through practical and theoretical knowledge. Consequently, it is mandatory to update the literature through previous and ongoing trials of vaccines tested among various ethnicities and age groups to gain a better insight into management strategies and combat complications associated with upcoming novel variants of SARS-CoV-2. |
| format | Article |
| id | my.ums.eprints-36746 |
| institution | Universiti Malaysia Sabah |
| language | en en |
| publishDate | 2023 |
| publisher | MDPI |
| record_format | eprints |
| spelling | my.ums.eprints-367462023-09-06T07:41:43Z https://eprints.ums.edu.my/id/eprint/36746/ Development of SARS-CoV-2 Vaccine: Challenges and Prospects Tooba Mahboob Amni Adilah Ismail Muhammad Raza Shah Mohammed Rahmatullah Alok K. Paul Maria de Lourdes Pereira Christophe Patrice Andie Wiart Polrat Wilairatana Mogana Rajagopal Karma G. Dolma Veeranoot Nissapatorn QR180-189.5 Immunology RA643-645 Disease (Communicable and noninfectious) and public health The WHO declared coronavirus disease 2019 (COVID-19) a pandemic in March 2020, which was caused by novel coronavirus severe acute respiratory coronavirus 2 (SARS-CoV-2). SARS-CoV-2 made its first entry into the world in November 2019, and the first case was detected in Wuhan, China. Mutations in the SARS-CoV-2 genome distressed life in almost every discipline by the extended production of novel viral variants. In this article, authorized SARS-CoV-2 vaccines including mRNA vaccines, DNA vaccines, subunit vaccines, inactivated virus vaccines, viral vector vaccine, live attenuated virus vaccines and mix and match vaccines will be discussed based on their mechanism, administration, storage, stability, safety and efficacy. The information was collected from various journals via electronic searches including PubMed, Science Direct, Google Scholar and the WHO platform. This review article includes a brief summary on the pathophysiology, epidemiology, mutant variants and management strategies related to COVID-19. Due to the continuous production and unsatisfactory understanding of novel variants of SARS-CoV-2, it is important to design an effective vaccine along with long-lasting protection against variant strains by eliminating the gaps through practical and theoretical knowledge. Consequently, it is mandatory to update the literature through previous and ongoing trials of vaccines tested among various ethnicities and age groups to gain a better insight into management strategies and combat complications associated with upcoming novel variants of SARS-CoV-2. MDPI 2023 Article NonPeerReviewed text en https://eprints.ums.edu.my/id/eprint/36746/1/ABSTRACT.pdf text en https://eprints.ums.edu.my/id/eprint/36746/2/FULL%20TEXT.pdf Tooba Mahboob and Amni Adilah Ismail and Muhammad Raza Shah and Mohammed Rahmatullah and Alok K. Paul and Maria de Lourdes Pereira and Christophe Patrice Andie Wiart and Polrat Wilairatana and Mogana Rajagopal and Karma G. Dolma and Veeranoot Nissapatorn (2023) Development of SARS-CoV-2 Vaccine: Challenges and Prospects. Diseases, 11. pp. 1-22. https://doi.org/10.3390/diseases11020064 |
| spellingShingle | QR180-189.5 Immunology RA643-645 Disease (Communicable and noninfectious) and public health Tooba Mahboob Amni Adilah Ismail Muhammad Raza Shah Mohammed Rahmatullah Alok K. Paul Maria de Lourdes Pereira Christophe Patrice Andie Wiart Polrat Wilairatana Mogana Rajagopal Karma G. Dolma Veeranoot Nissapatorn Development of SARS-CoV-2 Vaccine: Challenges and Prospects |
| title | Development of SARS-CoV-2 Vaccine: Challenges and Prospects |
| title_full | Development of SARS-CoV-2 Vaccine: Challenges and Prospects |
| title_fullStr | Development of SARS-CoV-2 Vaccine: Challenges and Prospects |
| title_full_unstemmed | Development of SARS-CoV-2 Vaccine: Challenges and Prospects |
| title_short | Development of SARS-CoV-2 Vaccine: Challenges and Prospects |
| title_sort | development of sars-cov-2 vaccine: challenges and prospects |
| topic | QR180-189.5 Immunology RA643-645 Disease (Communicable and noninfectious) and public health |
| url | https://eprints.ums.edu.my/id/eprint/36746/1/ABSTRACT.pdf https://eprints.ums.edu.my/id/eprint/36746/2/FULL%20TEXT.pdf https://eprints.ums.edu.my/id/eprint/36746/ https://doi.org/10.3390/diseases11020064 |
| url_provider | http://eprints.ums.edu.my/ |